Cardiac sudden death
Drug research and approvals for cardiac sudden death: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 65 studies of cardiac sudden death are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 65
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant EpilepsyNCT07888543 · Not applicable · Centre Hospitalier Universitaire, Amiens · starts Sep 10, 2026
- Molecular Autopsy in Young Individuals With Sudden Cardiac DeathNCT07849738 · Not reported · University of Sao Paulo · starts Jan 8, 2025
- Mitral Valve Prolapse Arrhythmic RiskNCT07830888 · Not reported · Oslo University Hospital · starts Aug 7, 2026
- FEMART-1 Pilot StudyNCT07596446 · Not applicable · Emergency Medical Service, Prague · starts May 11, 2026
- FAPI PET/CT Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) (FAPI-ARVC))NCT07563660 · Not applicable · Istanbul University - Cerrahpasa · starts Apr 16, 2025
- ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic…NCT07545512 · Not applicable · University Hospital, Clermont-Ferrand · starts Sep 24, 2026
- Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated CardiomyopathyNCT07527715 · Not reported · Shandong Provincial Hospital · starts Dec 1, 2021
- Validation of Sudden Cardiac Arrest Risk Factors in Patients With CADNCT07444931 · Not reported · Tampere Heart Hospital · starts Jan 5, 2025
- Loop Recorder Implantation in Patients With Mitral Annular DisjunctionNCT07436962 · Not applicable · Gottsegen National Cardiovascular Institute · starts Dec 5, 2025
Phase 3 12
- AmiodaroneHERG blocker
- SotalolBeta-1 adrenergic receptor antagonist
- ImipramineSerotonin transporter inhibitor
- MexiletineSodium channel alpha subunit blocker
- ProcainamideSodium channel alpha subunit blocker
- PropranololBeta-1 adrenergic receptor antagonist
- QuinidineSodium channel alpha subunit blocker
- PropafenoneBeta-1 adrenergic receptor antagonist
- TriamtereneAmiloride-sensitive sodium channel, ENaC blocker
- TenecteplaseTissue-type plasminogen activator exogenous protein
- HydrochlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- ChlorthalidoneThiazide-sensitive sodium-chloride cotransporter inhibitor
Phase 2 10
- EpinephrineAdrenergic receptor agonist
- VasopressinVasopressin receptor agonist
- MetoprololBeta-1 adrenergic receptor antagonist
- ErgocalciferolVitamin D receptor agonist
- Nitric oxideSoluble guanylate cyclase activator
- AlfacalcidolVitamin D receptor agonist
- UbidecarenoneSupplement
- OxygenEssential for cellular homeostasis
- Nitrogen
- Arginine butyrate
Phase 1 or earlier 1
- Fish oil triglyceridesSupplement
How its trials ended
276 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 48 whose ending is known, 44% met their primary endpoint, 15% missed it and 42% stopped early.
- Completed, result not reported11642%
- Ongoing6022%
- Status unknown5219%
- Met its primary endpoint218%
- Stopped: other or unclear93%
- Missed its primary endpoint73%
- Stopped: enrollment or feasibility73%
- Stopped: funding31%
- Stopped: lack of efficacy1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA